These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 27781946)

  • 1. The Role of Clusterin in Carcinogenesis and its Potential Utility as Therapeutic Target.
    Tellez T; Garcia-Aranda M; Redondo M
    Curr Med Chem; 2016; 23(38):4297-4308. PubMed ID: 27781946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer.
    Miyake H; Hara I; Fujisawa M; Gleave ME
    Expert Opin Investig Drugs; 2006 May; 15(5):507-17. PubMed ID: 16634689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticlusterin treatment of breast cancer cells increases the sensitivities of chemotherapy and tamoxifen and counteracts the inhibitory action of dexamethasone on chemotherapy-induced cytotoxicity.
    Redondo M; Téllez T; Roldan MJ; Serrano A; García-Aranda M; Gleave ME; Hortas ML; Morell M
    Breast Cancer Res; 2007; 9(6):R86. PubMed ID: 18078515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer.
    Gleave ME; Miyake H; Zellweger T; Chi K; July L; Nelson C; Rennie P
    Urology; 2001 Aug; 58(2 Suppl 1):39-49. PubMed ID: 11502446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Potential of Clusterin Inhibition in Human Cancer.
    Martín-García D; García-Aranda M; Redondo M
    Cells; 2024 Apr; 13(8):. PubMed ID: 38667280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The inhibition of angiogenesis by antisense oligonucleotides to clusterin.
    Jackson JK; Gleave ME; Gleave J; Burt HM
    Angiogenesis; 2005; 8(3):229-38. PubMed ID: 16308731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clusterin Expression in Colorectal Carcinomas.
    Téllez T; Martin-García D; Redondo M; García-Aranda M
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response of bladder carcinoma cells to TRAIL and antisense oligonucleotide, Bcl-2 or clusterin treatments.
    Sun B; Moibi JA; Mak A; Xiao Z; Roa W; Moore RB
    J Urol; 2009 Mar; 181(3):1361-71. PubMed ID: 19157446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors.
    Liu T; Liu PY; Tee AE; Haber M; Norris MD; Gleave ME; Marshall GM
    Eur J Cancer; 2009 Jul; 45(10):1846-54. PubMed ID: 19342222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of Clusterin Gene Expression.
    Garcia-Aranda M; Serrano A; Redondo M
    Curr Protein Pept Sci; 2018; 19(6):612-622. PubMed ID: 28925903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of clusterin mediates sensitivity to protein kinase inhibitors in breast cancer cells.
    Redondo M; García-Aranda M; Roldan MJ; Callejón G; Serrano A; Jiménez E; Téllez T
    Anticancer Drugs; 2015 Jan; 26(1):85-9. PubMed ID: 25144344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer.
    Shannan B; Seifert M; Leskov K; Willis J; Boothman D; Tilgen W; Reichrath J
    Cell Death Differ; 2006 Jan; 13(1):12-9. PubMed ID: 16179938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clusterin as modulator of carcinogenesis: A potential avenue for targeted cancer therapy.
    Praharaj PP; Patra S; Panigrahi DP; Patra SK; Bhutia SK
    Biochim Biophys Acta Rev Cancer; 2021 Apr; 1875(2):188500. PubMed ID: 33385484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clusterin: Review of research progress and looking ahead to direction in hepatocellular carcinoma.
    Xiu P; Dong XF; Li XP; Li J
    World J Gastroenterol; 2015 Jul; 21(27):8262-70. PubMed ID: 26217078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer.
    Gleave M; Miyake H
    World J Urol; 2005 Feb; 23(1):38-46. PubMed ID: 15770517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clusterin and DNA repair: a new function in cancer for a key player in apoptosis and cell cycle control.
    Shannan B; Seifert M; Boothman DA; Tilgen W; Reichrath J
    J Mol Histol; 2006 Sep; 37(5-7):183-8. PubMed ID: 17048076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of clusterin in prostate cancer: treatment resistance and potential as a therapeutic target.
    Muhammad LA; Saad F
    Expert Rev Anticancer Ther; 2015; 15(9):1049-61. PubMed ID: 26313417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic.
    Miyake H; Hara I; Gleave ME
    Int J Urol; 2005 Sep; 12(9):785-94. PubMed ID: 16201973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of clusterin (CLU) in malignant transformation and drug resistance in breast carcinomas.
    Redondo M; Tellez T; Roldan MJ
    Adv Cancer Res; 2009; 105():21-43. PubMed ID: 19879421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Short-term neoadjuvant hormone therapy enhanced expression of clusterin in prostate cancer].
    Niu YN; Xin DQ; He ZS; Zhou LQ; Pan BN; Na YQ; Guo YL
    Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):394-7. PubMed ID: 15854351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.